R. Rehfuss

发表

A dominant repressor of cyclic adenosine 3',5'-monophosphate (cAMP)-regulated enhancer-binding protein activity inhibits the cAMP-mediated induction of the somatostatin promoter in vivo.

R. Goodman, K. Walton, R. Rehfuss, 1992, Molecular endocrinology.

Site-specific binding constants for actinomycin D on DNA determined from footprinting studies.

R. Rehfuss, J. Goodisman, J. Dabrowiak, 1992, Biochemistry.

Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of Pharmacology and Experimental Therapeutics.

Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of cardiovascular pharmacology.

Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases

A. Yamniuk, S. Grant, J. Bryson, 2014, The Journal of Immunology.

Actinomycin D facilitates transition of AT domains in molecules of sequence (AT)nAGCT(AT)n to a DNAse I detectable alternating structure.

C. Cantor, P. Borer, S. LaPlante, 1987, Nucleic acids research.

Actinomycin D induced DNase I cleavage enhancement caused by sequence specific propagation of an altered DNA structure.

P. Borer, S. LaPlante, R. Rehfuss, 1988, Nucleic acids research.

Identification and Characterization of a Novel Transcriptional Activation Domain in the CREB-binding Protein*

R. Rehfuss, S. Bisotto, S. Minorgan, 1996, The Journal of Biological Chemistry.

Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

P. Lam, Hong Shen, A. Mathur, 2014, Bioorganic & medicinal chemistry letters.

Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.

P. Lam, Hong Shen, R. Rehfuss, 2014, Journal of medicinal chemistry.

Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

P. Lam, R. Rehfuss, D. Seiffert, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.

J. Y. Roberge, D. Schnur, A. Cacace, 2013, Journal of medicinal chemistry.

2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists.

P. Lam, Hong Shen, R. Rehfuss, 2014, Bioorganic & medicinal chemistry letters.

Rate enhancements in the DNase I footprinting experiment.

R. Rehfuss, J. Goodisman, J. Dabrowiak, 1988, Nucleic acids research.

The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.

R. Goodman, M. Loriaux, K. Walton, 1991, The Journal of biological chemistry.

Esperamicins, a class of potent antitumor antibiotics: mechanism of action.

J. Catino, R. Rehfuss, S. Forenza, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

Steven A. Spronk, P. Lam, D. Schnur, 2013, Journal of medicinal chemistry.

Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds.

P. Lam, R. Rehfuss, R. Ruel, 2013, Bioorganic & medicinal chemistry letters.

2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.

P. Lam, R. Rehfuss, Christine S. Huang, 2013, Bioorganic & medicinal chemistry letters.

New azole antagonists with high affinity for the P2Y(1) receptor.

P. Lam, R. Rehfuss, R. Ruel, 2013, Bioorganic & medicinal chemistry letters.

ANALYSIS OF NEUROPEPTIDE GENE EXPRESSION BY TRANSFECTION

R. Rehfuss, C. Inês, Kevin M. Wahon, 1993 .

3',5'-cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line.

R. Cone, R. Goodman, K. Walton, 1992, Molecular endocrinology.

Somatostatin gene regulation: an overview.

M. Low, R. Goodman, R. Rehfuss, 1990, Metabolism: clinical and experimental.

Clopidogrel versus prasugrel in rabbits

R. Rehfuss, P. Wong, W. Schumacher, 2008, Thrombosis and Haemostasis.

Molecular mechanisms of cAMP-regulated gene expression

K. Walton, R. Rehfuss, 2007, Molecular Neurobiology.

Analysis of neuropeptide gene expression by transfection of DNA into cell lines

K. Walton, R. Rehfuss, 1993 .

Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active.

R. Brennan, R. Goodman, M. Loriaux, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene.

R. Rehfuss, G. Hendy, A. Mouland, 1998, Endocrinology.

Diseases Antibody for Treatment of Autoimmune Engineering of a Novel Anti-CD 40 L Domain

A. Yamniuk, S. Grant, J. Bryson, 2014 .

4‐Benzothiazole‐7‐hydroxyindolinyl Diaryl Ureas Are Potent P2Y1 Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution

Steven A. Spronk, P. Lam, Hong Shen, 2014, ChemMedChem.

Specific cleavage of the yeast genome at 5'-ATCGATCGAT-3'.

R. Rehfuss, A. Smardon, M. Lane, 1989, Nucleic Acids Research.

Determination of netropsin-DNA binding constants from footprinting data.

R. Rehfuss, J. Goodisman, J. Dabrowiak, 1988, Biochemistry.